A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma

被引：11

作者：

Bennouna, J

Delva, R

Gomez, F

Lesimple, T

Geoffrois, L

Linassier, C

Chevreau, C

Douillard, JY

Négrier, S

机构：

[1] Ctr Rene Gauducheau, F-44805 Nantes, France

[2] Ctr Paul Papin, Angers, France

[3] Ctr Leon Berard, F-69373 Lyon, France

[4] Ctr Eugene Marquis, Rennes, France

[5] Ctr Alexis Vautrin, Nancy, France

[6] CHRU Bretonneau, Tours, France

[7] Inst Claudius Regaud, Toulouse, France

来源：

ONCOLOGY | 2003年 / 64卷 / 01期

关键词：

metastatic renal cell carcinoma; 5-FU; oxaliplatin;

D O I：

10.1159/000066518

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To investigate the efficacy and safety of the FOLFOX-4 regimen for patients with metastatic renal cell carcinoma (MRCC). Patients and Methods: Fifty-nine patients (median age 59 years) pre-treated or not by cytokines (29 vs. 30) received the FOLFOX-4 regimen every 2 weeks. Results: Three minor responses, and no complete or partial responses were obtained. The median progression-free survival was 3 months (95% Cl: 2.6-3.4), the median survival 10.6 months (95% Cl: 8.7-12.4), with no difference between pre-treated patients and others. Treatment was well tolerated. Conclusion: The FOLFOX-4 regimen is ineffective in patients with MRCC. We believe that oxaliplatin should no longer be explored in renal carcinoma. Copyright (C) 2003 S. Karger AG, Basel.

引用

收藏

页码：25 / 27

页数：3

相关论文

共 10 条

[1] Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma - Results of a pilot study [J].

Chaouche, M ;

Pasturaud, AL ;

Kamioner, D ;

Grandjean, M ;

Franiatte, J ;

Tourani, JM .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (03) :288-289

[2]

Chauffert B, 1998, PRESSE MED, V27, P859

[3] Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].

Childs, R ;

Chernoff, A ;

Contentin, N ;

Bahceci, E ;

Schrump, D ;

Leitman, S ;

Read, EJ ;

Tisdale, J ;

Dunbar, C ;

Linehan, WM ;

Young, NS ;

Barrett, AJ ;

Clave, E ;

Epperson, D ;

Mayo, V .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758

[4] PHASE-II TRIAL OF TAXOL IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA [J].

EINZIG, AI ;

GOROWSKI, E ;

SASLOFF, J ;

WIERNIK, PH .

CANCER INVESTIGATION, 1991, 9 (02) :133-136

[5] Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer [J].

Fizazi, K ;

Ducreux, M ;

Ruffié, P ;

Bonnay, M ;

Daniel, C ;

Soria, JC ;

Hill, C ;

Fandi, A ;

Poterre, M ;

Smith, M ;

Armand, JP .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) :2293-2300

[6] RETRACTED: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids (Retracted article. See vol. 9, p. 1221, 2003) [J].

Kugler, A ;

Stuhler, G ;

Walden, P ;

Zöller, G ;

Zobywalski, A ;

Brossart, P ;

Trefzer, U ;

Ullrich, S ;

Müller, CA ;

Becker, V ;

Gross, AJ ;

Hemmerlein, B ;

Kanz, L ;

Müller, GA ;

Ringert, RH .

NATURE MEDICINE, 2000, 6 (03) :332-336

[7] GEMCITABINE IN ADVANCED RENAL-CELL CARCINOMA - A PHASE-II STUDY OF THE NATIONAL-CANCER-INSTITUTE OF CANADA-CLINICAL-TRIALS-GROUP [J].

MERTENS, WC ;

EISENHAUER, EA ;

MOORE, M ;

VENNER, P ;

STEWART, D ;

MULDAL, A ;

WONG, D .

ANNALS OF ONCOLOGY, 1993, 4 (04) :331-332

[8]

Motzer Robert J., 1997, P885

[9] Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma [J].

Negrier, S ;

Escudier, B ;

Lasset, C ;

Douillard, JY ;

Savary, J ;

Chevreau, C ;

Ravaud, A ;

Mercatello, A ;

Peny, J ;

Mousseau, M ;

Philip, T ;

Tursz, T .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) :1272-1278

[10] Kidney cancer [J].

Vogelzang, NJ ;

Stadler, WM .

LANCET, 1998, 352 (9141) :1691-1696